NCT03591510 2026-03-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT02115295 2025-11-06
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03836209 2025-06-15
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
PrECOG, LLC.
Phase 2 Active not recruiting
NCT03280030 2025-03-20
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Novartis
Phase 2 Completed
NCT03951961 2022-01-21
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
University of Jena
Phase 2 Terminated
NCT01883362 2021-03-17
RADIUS
Novartis
Phase 2 Completed
NCT01830361 2020-08-06
MIDOKIT
Technische Universität Dresden
Phase 2 Completed
NCT01477606 2020-06-04
Protocol in Acute Myeloid Leukemia With FLT3-ITD
University of Ulm
Phase 2 Completed
NCT00782067 2018-11-15
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Novartis
Phase 2 Completed
NCT03207334 2018-10-22
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
Phase 2 Withdrawn
NCT01846624 2018-09-27
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Stanford University
Phase 2 Terminated
NCT00233454 2018-09-20
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Stanford University
Phase 2 Completed
NCT01920204 2015-01-19
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
Phase 2 Unknown